Calon-Cardio's Fully Implantable ventricular assist device

Calon-Cardio 的完全植入式心室辅助装置

• 批准号: 10037229
• 金额: $ 62.55万
• 依托单位: CALON CARDIO-TECHNOLOGY LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10037229
• 关键词: Calon; Cardio; Fully; Implantable; ventricular

The majority of chronic heart disease patients ultimately suffer from heart failure. With the ageing of the population and advances in the treatment of cardiac disease, the number of patients with heart failure continues to increase. Although the majority of patients will remain stable for several years with standard medicines and surgery, a growing number will develop symptoms of advanced heart failure and may be referred for evaluation for heart transplantation. For selected patients who are too ill to wait for a heart donor or who are not eligible for a heart transplant because of age or other medical problems, ventricular assist devices (VADs) offer life-saving therapy and the only hope of returning to a good quality of life. Initially designed as temporary support to bridge patients to heart transplant, these devices are now being used as lifetime support or destination therapy. However, current technology is still imperfect with a recognised need to manage adverse events (AEs).This project will develop a Fully Implantable VAD to specifically address the main weaknesses of current VADs with a pump that offers improved haemodynamic performance, the elimination of driveline infection risk, lower manufacture and lifetime costs, and gives patients the freedom to perform everyday tasks unencumbered.The novel design of our new FIVAD will bring together expertise in mechanical engineering, electrical engineering, computational fluid dynamics, and biomedical engineering to deliver a novel pump and wireless energy technology.

大多数慢性心脏病患者最终都会遭受心力衰竭。随着人口老龄化和心脏病治疗的进步，心力衰竭患者数量持续增加。尽管大多数患者通过标准药物和手术可以在数年内保持稳定，但越来越多的患者会出现晚期心力衰竭的症状，并可能被转诊进行心脏移植评估。对于因病重而无法等待心脏捐赠者或因年龄或其他医疗问题而没有资格进行心脏移植的特定患者，心室辅助装置 (VAD) 可以提供挽救生命的治疗，也是恢复良好状态的唯一希望。生活质量。这些设备最初设计为临时支持，以帮助患者接受心脏移植，现在被用作终生支持或目标治疗。然而，目前的技术仍然不完善，需要管理不良事件 (AE)。该项目将开发一种完全植入式 VAD，专门解决当前 VAD 的主要弱点，其泵可提供改善的血液动力学性能，消除传动系统感染风险，降低制造和生命周期成本，并让患者能够自由地执行日常任务。我们的新型 FIVAD 的新颖设计将汇集机械工程、电气工程、计算流体动力学和生物医学工程方面的专业知识，提供一种新型泵和无线能源技术。